Aptevo Therapeutics (APVO) director converts 400 RSUs into common shares
Rhea-AI Filing Summary
Aptevo Therapeutics Inc. director Zsolt Harsanyi reported a derivative exercise involving restricted stock units. On August 6, 2026, 400 RSUs were converted on a one-for-one basis into 400 shares of common stock, with no per-share exercise price reported. The RSU position was reduced to 0, and direct ownership of common stock increased to 400 shares. The RSUs originated from a grant made on August 6, 2025, which vested on the first anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 400 shares
Net Buy
2 txns
Insider
Harsanyi Zsolt
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit F1, F2 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 400 | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 shares (Direct);
Common Stock — 400 shares (Direct)
Footnotes (2)
- F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
- F2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
Key Figures
RSUs exercised: 400 units
Common shares acquired: 400 shares
Common shares held after transaction: 400 shares
+1 more
4 metrics
RSUs exercised
400 units
Restricted Stock Units converted into common stock on August 6, 2026
Common shares acquired
400 shares
Common stock received upon RSU conversion on August 6, 2026
Common shares held after transaction
400 shares
Direct ownership of Aptevo common stock following the reported transactions
Original RSU grant (post-split)
400 units
RSUs granted on August 6, 2025 (7,200 pre-split, 400 post-split), vesting after one year
Key Terms
Restricted Stock Unit, derivative security, par value per share, vests
4 terms
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"transaction_action": "derivative exercise/conversion""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vests financial
"RSUs, vesting on the first anniversary of the date of grant"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Aptevo Therapeutics (APVO) director Zsolt Harsanyi report?
Director Zsolt Harsanyi reported exercising 400 restricted stock units into 400 shares of Aptevo common stock on August 6, 2026. This was recorded as an exercise or conversion of a derivative security.
How many Aptevo Therapeutics (APVO) RSUs did Zsolt Harsanyi convert and what did he receive?
He converted 400 restricted stock units into 400 shares of common stock of Aptevo Therapeutics. The RSUs converted on a one-for-one basis into common shares as described in the filing footnotes.
What are Zsolt Harsanyi’s Aptevo (APVO) holdings after this Form 4 transaction?
After the reported transactions, Zsolt Harsanyi directly holds 400 shares of Aptevo common stock and 0 restricted stock units from this grant. No additional derivative positions are listed in the filing’s derivative summary.
When were the Aptevo (APVO) RSUs originally granted to Zsolt Harsanyi?
The RSUs were granted on August 6, 2025, originally for 7,200 units (noted as 400 post-split) and were scheduled to vest on the first anniversary of the grant date, according to the footnote disclosure.
Did Aptevo (APVO) indicate a 10b5-1 trading plan for Zsolt Harsanyi’s Form 4 transaction?
The filing’s Rule 10b5-1 checkbox was not marked as an affirmative plan, and there is no footnote stating that the exercise occurred pursuant to a pre-arranged trading plan.